The role of fish oil in arrhythmia prevention.
Anand RG et al.
J Cardiopulm Rehabil Prev. 2008;28:92-8
This review focuses on how fish oil therapy has performed in 3 primary prevention trials in patients with implantable cardioverter defibrillators, reviews the effects that fish oil has on the autonomic nervous system, focuses on the use of fish oil as a novel therapy for atrial fibrillation, and revisits other beneficial properties of fish oil (ie, ability to lower serum triglycerides, anti-inflammatory effects, and possible improvements in arterial pressure/diastolic function). The review recommends considering fish oil supplementation for any patient with documented coronary heart disease and those with risk factors for sudden cardiac death, such as left ventricular dysfunction, left ventricular hypertrophy, prior myocardial infarction, or high-grade ventricular dysrhythmias; using doses of eicosapentanoic acid and docosahexanoic acid in the combined range of 800 to 1000 mg/day for primary and secondary prevention of cardiovascular disease.
Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both?
von Schacky C.
Curr Opin Clin Nutr Metab Care. 2008;11:94-9.
This comprehensive review of the effects of omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid on cardiac rhythm considers the evidence to be overwhelming in favour of an antiarrhythmic effect.
Critical Analysis of GISSI-Prevenzione Trial. Highly purified omega-3 polyunsaturated fatty acids are effective as adjunct therapy for secondary prevention of myocardial infarction.
Verboom CN
Herz. 2006;31 Suppl 3:49-59.
The GISSI-Prevenzione was the first large randomised trial to show that omega-3 polyunsaturated fatty acids
(1 g/day), administered as an adjunct to other accepted interventions (antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme [ACE] inhibitors), had a favourable effect on hard clinical endpoints in post-myocardial infarction patients.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment